Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.
Request Insights
IN THE NEWSMarch 11th, 2019: Hitachi, Ltd. announced that for the first time in Japan, it has launched the automated cell mass culture equipment. This equipment, which was first deployed at Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine & Cell Therapy (SMaRT) of Sumitomo Dainippon Pharma Co., Ltd., is able to manufacture commercial iPS cells for regenerative medicine.
March 22nd, 2021: Thermo Fisher Scientific Inc. announced that it has launched the new Gibco Human Plasma-like Medium (HPLM), a cell culture medium that mimics the metabolic profile of human plasma. The cell culture medium, which is first of its type, is designed to provide researchers with a realistic view of cell growth within the human body.
The global automated cell culture market is estimated to garner a revenue of USD 26411.9 Million by the end of 2031 by growing at a CAGR of 8.7% over the forecast period, i.e., 2022 – 2031. Moreover, in the year 2021, the market generated a revenue of USD 11506.8 Million. The growth of the market can majorly be attributed to the rising incidence of chronic and infectious diseases worldwide, and therefore the need for advanced drugs that can help to treat the patients. According to the statistics by the World Health Organization (WHO), each year 41 Million people are known to die from noncommunicable diseases (NCDs). Moreover, the statistics also stated that between the ages of 30 and 69 years, more than 15 Million people are known to die from a NCD each year. An automated cell culture system allows large-scale production of cells. Since the production process involves high precision technicalities, as well as greater reproducibility and efficiency, hence these processes are known to be highly effective for the manufacturing of advanced drugs that are used for the treatment of different types of chronic diseases.
Get more information on this report: Request Sample PDF
One of the other factors anticipated to drive the growth of the global automated cell culture market is the high manufacturing efficiency of the production process, which significantly lowers the probability of an error as well repetitive manual work, which otherwise are involved in a conventional manufacturing process. Besides this, the surge in investment for research activities in the field of medical science is also expected to create numerous opportunities for market growth during the forecast period.
Regionally, the global automated cell culture market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is projected to garner the largest revenue of USD 11542.0 Million by the end of 2031, up from a revenue of USD 5104.0 Million in the year 2021. The growth of the market in the region can primarily be attributed to the surge in demand for personalized medicine, surge in R&D activities related to cancer and other chronic diseases, increasing R&D expenditure, and for the presence of major players in the region. According to the statistics by the National Cancer Institute (NCI) of the United States Department of Health and Human Services (National Institutes of Health), the NCI budget for funding for research in cancer touched USD 6440.4 Million by the end of 2020, up from USD 4952.6 Million in the year 2015. On the other hand, the market in Europe is projected to garner the second-largest revenue of USD 6790.5 Million by the end of 2031, up from a revenue of USD 2954.7 Million in the year 2021. The market in the region is further segmented by country into Germany, United Kingdom, Italy, France, Spain, Russia, Netherlands, and the Rest of Europe. The market in Germany is projected to garner the largest revenue of USD 1333.0 Million by the end of 2031, up from a revenue of USD 540.7 Million in the year 2021.
The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Challenges
The global automated cell culture market is segmented by product into consumables and equipment, out of which, the equipment segment is anticipated to garner the highest market share by the end of 2031. By application, the market is segmented into biopharmaceutical production, tissue engineering & regenerative medicine, drug screening & development, gene therapy, stem cell research, diagnostics, toxicity testing, and others. The biopharmaceutical production segment is anticipated to garner the largest revenue of USD 5870.5 Million by the end of 2031, up from a revenue of USD 2526.3 Million in the year 2021. By end-user, the market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and others. The pharmaceutical & biotechnology companies segment is expected to garner the largest revenue of USD 11671.6 Million by the end of 2031, up from a revenue of USD 4845.7 Million in the year 2021.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global automated cell culture market that are included in our report are Hitachi, Ltd., Thermo Fisher Scientific, Inc., Sartorius AG, Hamilton Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Becton, Dickinson and Company, Cell Culture Company, LLC, Lonza Group, and others.
FREQUENTLY ASKED QUESTIONS
The growing incidence of chronic and infectious diseases, and the numerous benefits associated with the use of automated cell culture processes are some of the major factors anticipated to drive the growth of the market.
The market is anticipated to attain a CAGR of 8.7% over the forecast period, i.e., 2022 – 2031.
The higher cost associated with the use of the cell culture process is one of the major factors estimated to hamper the market growth.
The market in North America is projected to garner the largest revenue of USD 11542.0 Million by the end of 2031 and provide more business opportunities in the future.
The major players in the market are Hitachi, Ltd., Thermo Fisher Scientific, Inc., Sartorius AG, Hamilton Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Becton, Dickinson and Company, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product, application, end-user, and by region.
The biopharmaceutical production segment is anticipated to garner the largest revenue of USD 5870.5 Million by the end of 2031 and display significant growth opportunities.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
